---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024723"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T20:31:45.027013+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Crinetics Q3 net loss widens to $41.9M; paltusotine Phase 3 on track for Q3 2023 topline

## Summary
- Net loss $41.9M in Q3 2022 vs $27.9M in Q3 2021; R&D spend rose to $32.0M from $21.6M.
- Cash and investments $368.4M as of Sep 30, 2022, up from $333.7M at Dec 31, 2021.
- Phase 3 PATHFNDR-1 for paltusotine in acromegaly fully enrolled; topline data expected Q3 2023.
- Long-term extension data: paltusotine maintained IGF-1 comparable to injected SRLs for up to 103 weeks; 89% preferred paltusotine.
- Appointed Dana Pizzuti, M.D. as chief development officer.

## SEC filing metadata
- accession: 0000950170-22-024723
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000095017022024723/0000950170-22-024723-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000095017022024723/crnx-20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024723
- JSON: https://secwatch.observer/filing/0000950170-22-024723.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024723.txt

## Key facts
- Earnings Releases
  Crinetics Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue $0.5 million, net income $41.9 million.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $0.5 million
  - Net income: $41.9 million
  - Result: reported results
  source text: $3.0 million. • Net loss for the three months ended September 30, 2022, was $41.9 million, compared to a net loss of $27.9 million for the same period in 2021. • Revenues were $0.5 million for the three months ended September 30, 2022, consisting of license revenue recognized from the license agreement entered into with Sanwa Kagaku Kenkyusho Co., Ltd. in February
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658247/000095017022024723/0000950170-22-024723-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.